"We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS.
Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings ... .